BETA
Your AI-Trained Oncology Knowledge Connection!
Divya Gupta, MD, presents data from CHRYSALIS-2 focused on amivantamab plus lazertinib in atypical EGFR-mutated advanced non–small cell lung cancer.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
An International Search for Lung Cancer Treatment Leads to Double Lung Transplant
The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC
Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Neoadjuvant Osimertinib Enhances Responses in Resectable EGFR-Mutated NSCLC
An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.
Dermatologic Management Sustains QOL After Amivantamab Combo in EGFR+ NSCLC
Most patients who received COCOON dermatologic management reported mild or no dermatologic symptoms following treatment with amivantamab/lazertinib.